Cover Image
Market Research Report

Ocular Hypertension Global Clinical Trials Review, H1, 2016

Published by GlobalData Product code 242620
Published Content info 370 Pages
Immediate Delivery Available
Price
Back to Top
Ocular Hypertension Global Clinical Trials Review, H1, 2016
Published: March 31, 2016 Content info: 370 Pages
Description

GlobalData's clinical trial report, "Ocular Hypertension Global Clinical Trials Review, H1, 2016" provides an overview of Ocular Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Ocular Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
Product Code: GDHC3309CTIDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Ocular Hypertension to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Ocular Hypertension to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Ocular Hypertension Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Ocular Hypertension
      • Mar 17, 2016: Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa QD (netarsudil ophthalmic solution) 0.02%
      • Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting
      • Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2
      • Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Ocular Hypertension Therapeutics, Global, Clinical Trials by Region, 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Ocular Hypertension to Ophthalmology Clinical Trials, G7 Countries (%), 2016*
  • Ocular Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Ocular Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Ocular Hypertension to Ophthalmology Clinical Trials, E7 Countries (%), 2016*
  • Ocular Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Ocular Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Ocular Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Ocular Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Ocular Hypertension to Ophthalmology Clinical Trials, G7 Countries (%), 2016*
  • Ocular Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Ocular Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Ocular Hypertension to Ophthalmology Clinical Trials, E7 Countries (%), 2016*
  • Ocular Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Ocular Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Ocular Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Ocular Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Ocular Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top